European experience with flurbiprofen: A new analgesic/anti-inflammatory agent

Buchanan, W. Watson; Kassam, Yasmin B.

doi:10.1016/0002-9343(86)90134-8

Cited by 34 publications

(10 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Flurbiprofen is a non-steroidal anti-inflammatory drug (NSAID) with proven analgesic and anti-inflammatory effects,18,19 and lozenges containing 8.75 mg flurbiprofen have been shown to be safe and effective in relieving the symptoms of a sore throat (including pain) 3,20–24. Flurbiprofen 8.75 mg lozenges are available over-the-counter in many countries, and they are the only formulation of flurbiprofen currently available in Russia.…”

Section: Introductionmentioning

confidence: 99%

Efficacy of flurbiprofen 8.75 mg delivered as a spray or lozenge in patients with sore throat due to upper respiratory tract infection: a randomized, non-inferiority trial in the Russian Federation

Radkova¹,

Burova²,

Bychkova³

et al. 2017

JPR

View full text Add to dashboard Cite

ObjectiveTo assess the efficacy of flurbiprofen 8.75 mg delivered as a spray or lozenge in patients with sore throat due to upper respiratory tract infection (URTI).Materials and methodsThis multicenter, double-blind, double-dummy, non-inferiority study randomized 440 adults with recent-onset, moderate-to-severe sore throat due to URTI to a single dose of either flurbiprofen 8.75 mg spray (n=218) or flurbiprofen 8.75 mg lozenge (n=222). The presence or absence of beta-hemolytic streptococci (A or C) was confirmed by culture tests (throat swab). The primary efficacy end point was the difference from baseline to 2 hours post-dose in sore throat pain intensity scale (STPIS pain intensity difference [PID] 2h), a validated 100 mm visual analog scale (from 0=“no pain” to 100=“severe pain”), with a non-inferiority margin of −6 mm. Secondary end points included STPIS PID at 1 hour (STPIS PID 1h) and over 2 hours (STPIS sum of sore throat pain intensity differences [SPID]0–2h) and ratings of patient satisfaction and investigator assessment of drug efficacy at 2 hours. Safety (adverse events [AEs]) was also assessed.ResultsReductions in sore throat pain intensity at 2 hours (STPIS PID 2h) were similar for spray (least square mean −40.51) and lozenge (−40.10) (difference: 0.41, 95% confidence interval [95% CI] −3.20, 4.01), with non-inferiority demonstrated. Subgroup analyses showed similar efficacy (STPIS PID 2h) for patients testing positive or negative for Strep A or C. There was no significant difference between spray and lozenge in STPIS PID 1h or STPIS SPID0–2h, and patient satisfaction and investigators’ assessment of efficacy at 2 hours were similar for both groups. There were no significant differences in AEs between the two groups, with 17 drug-related events across both groups, all being mild and none being serious.ConclusionBoth formulations demonstrated comparable efficacy and safety profiles and provide patients with two different treatment formats to choose from for effective symptomatic relief of sore throat, depending on their preference.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy of flurbiprofen 8.75 mg delivered as a spray or lozenge in patients with sore throat due to upper respiratory tract infection: a randomized, non-inferiority trial in the Russian Federation

Radkova¹,

Burova²,

Bychkova³

et al. 2017

JPR

View full text Add to dashboard Cite

show abstract

“…The third limitation is that we could not measure what percent of flurbiprofen is bound to protein in the measured tissues. It is known that, in blood, 99% of flurbiprofen is bound to protein (mainly to albumin), and only the remaining 1% is available to exert a clinical effect [5][6][7].We speculate that a similar percentage of flurbiprofen may be available to exert a clinical effect in the tissues, because flurbiprofen is confirmed to have a pain-reducing effect on these tissues. Further studies are needed to establish the clinical utility of topical application of flurbiprofen in comparison with oral administration.…”

Section: Discussionmentioning

confidence: 79%

“…Recently, we performed a randomized pharmacokinetic study to compare the concentrations of diclofenac in muscle, synovium and fat tissues between topical application and oral administration according to the regulatory approved dosing guidelines [4]. Concerning flurbiprofen, the effectiveness of oral administration has been sufficiently established [5,6]. However, no controlled studies have been conducted to compare the tissue concentration of flurbiprofen between topical application and oral administration, although the comparative pharmacokinetic data from a limited number of patients were available in the literature [7].…”

Section: Introductionmentioning

confidence: 99%

Flurbiprofen concentration in soft tissues is higher after topical application than after oral administration

Kai

Kondo

Kawaguchi

et al. 2013

Brit J Clinical Pharma

View full text Add to dashboard Cite

AIMTo compare tissue concentrations of flurbiprofen resulting from topical application and oral administration according to the regulatory approved dosing guidelines. METHODSixteen patients were included in this study. Each patient was randomly assigned to the topical application or oral administration group. In each group, a pair of tapes or a tablet, containing a total of 40 mg flurbiprofen, was administered twice at 16 and 2 h before the surgery. RESULTSThe flurbiprofen concentration in the fat, tendon, muscle and periosteum tissues was significantly higher (P < 0.0330) after topical application (992 ng CONCLUSIONTopical application is an effective method to deliver flurbiprofen to the human body, particularly to soft tissues near the body surface.

show abstract

“…Flurbiprofen and ketoprofen are racemic propionic acid-derived NSAIDs with proven efficacy and safety in the treatment of osteoarthritis, rheumatoid arthritis and acute musculoskeletal disorders (Brogden et., 1979;Buchanan & Kassam, 1986;Waikakul et al, 1997). As a matter of course, tape-type patches of flurbiprofen (FP-T) and ketoprofen (KP-T) have been used and investigated for their anti-inflammatory and analgesic effects on local tissues (Martens, 1997;Mazieres, 2005).…”

Section: Drugsmentioning

confidence: 99%